Topic: Gilenya
(Reuters) - U.S. health regulators said on Tuesday they received a report of a multiple sclerosis patient who died within 24 hours of taking the first dose of Novartis AG's Gilenya.The U.S. Food and Drug Administration said at this time, it cannot ...
ZURICH (Reuters) - A third late-stage trial of Novartis' multiple sclerosis drug Gilenya did not throw up any new safety issues with the pill, going some way to alleviating concerns about possible risks linked to the potential blockbuster.The study results come just ...
BOSTON (Reuters) - Over the past year, Biogen Idec Inc has given investors little to complain about. The biotechnology company, operating under new management, has restructured its operations, reported promising clinical trial data and seen its shares rise 72 percent.The question is: ...
LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its biggest new drug hopes, has been rejected by Britain's healthcare cost-effectiveness watchdog NICE, which judges it not worth using on the state health service.The National Institute for Health and Clinical Excellence ...
In September 2010, the U.S. Food and Drug Administration (FDA) approved the first oral drug for treating relapsing-remitting multiple sclerosis (MS). Gilenya, or fingolimod, has been shown to reduce relapses of MS and also, potentially, delay physical complications of the illness. Multiple ...
Novartis' Gilenya (formerly spelled Gilenia, generic name fingolimod) is the first treatment for multiple sclerosis that patients take as a once-daily pill (0.5 mg capsules). Gilenya does not cure MS, but it reduces the frequency of MS relapses (flare-ups) by a novel ...
Efforts underway to educate community and healthcare providers on Gilenya to enable informed treatment decisions. - Novartis launching initiatives to support broad patient access, including prescription benefits investigation services, co-pay programs, and inclusion of Gilenya in Novartis Patient Assistance Program. Novartis Pharmaceuticals ...
The U.S. Food and Drug Administration on Wednesday approved the first oral drug to treat multiple sclerosis, the nervous system disorder that has traditionally been treated with injectable drugs.. Gilenya (fingolimod) is designed to reduce relapses and delay the progression of debilitating ...
From Around the Web
Video Gallery
-
MS Update! Tysabri or Gilenya?
A short update regarding my recent relapse and change in ...2011-05-14 -
Gilenya Side Effects
Gilenya, the brand name for the generic fingolimod, is an ...2011-03-23 -
A Closer Look at Gilenya - The ...
MSAA's Chief Medical Officer Dr. Jack Burks answers 6 ...2010-09-28
